Patents Examined by Sreenivasan Padmanabhan
  • Patent number: 10791732
    Abstract: A water dispersible granular composition comprising: at least one solid agrochemically active substance; at least one sorptive filler; at least one first agrochemically acceptable excipient; at least one liquid or low melting agrochemically active substance; and, at least one second agrochemically acceptable excipient. The invention further relates to a process of preparing the water dispersible granular composition.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 6, 2020
    Assignee: DEEPAK PRANJIVANDAS SHAH
    Inventors: Deepak Pranjivandas Shah, Puthenveetil Kunjukrishna Menon Ramdas, Balachandran Thankappan Vadakkekuttu
  • Patent number: 10780113
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: September 22, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd.
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10736878
    Abstract: A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a triptan compound to a subject.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: August 11, 2020
    Inventor: Tina Pfadenhauer
  • Patent number: 10588832
    Abstract: The present application relates to sunscreen formulations, including foamable sunscreen formulations, that comprise zinc oxide and titanium dioxide particles, suitably in the size range of about 1-100 nm. The compositions suitably produce a minimal residual whitening effect when applied to a skin surface.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: March 17, 2020
    Assignee: FALLIEN COSMECEUTICALS, LTD.
    Inventors: David J. Milora, Harry Fallick
  • Patent number: 10478443
    Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: November 19, 2019
    Assignee: ENDORECHERCHE, INC.
    Inventors: Mohamed El-Alfy, Fernand Labrie, Louise Berger
  • Patent number: 10478427
    Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: November 19, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hiroyuki Nakamura, Toshihiko Murayama
  • Patent number: 10449177
    Abstract: The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: October 22, 2019
    Assignee: Buck Institute for Research on Aging
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 10450307
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: October 22, 2019
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Ke Liu
  • Patent number: 10426782
    Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 1, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Rachael L. Brake, Viviana Bozon, Ching-Kuo J. Chow, James C. Dinunzio, Katherine M. Galvin, Karuppiah Kannan, Yuki Kodono, Qunli Xu
  • Patent number: 10420776
    Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: September 24, 2019
    Assignee: RHINONASE, INC.
    Inventors: Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris
  • Patent number: 10413560
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 17, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10406234
    Abstract: Disclosed are methods of making oral pharmaceutical compositions that contain substantially crush resistant drug containing microparticles. The microparticles may contain an active pharmaceutical agent, a polymer and a plasticizer. The microparticles may be un-coated (so as to impart an immediate release profile) or coated so as to impart an extended release (ER), delayed release (DR) or delayed extended release (DER) profile. One or more of the populations of microparticles may be coated with a taste masking composition. The methods may produce oral compositions such as orally disintegrating tablets that contain one or more these types of microparticles in order to further customize the release profile. Also disclosed are the oral compositions, per se, and methods of using same for their intended purposes.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: September 10, 2019
    Assignee: Kashiv BioSciences, LLC
    Inventors: Siva Ram Kiran Vaka, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah, Kanji Meghpara
  • Patent number: 10391086
    Abstract: The invention is a method of treating osteoarthritis or normalizing a condition of osteoarthritis comprising administering to an animal or a human in need thereof a therapeutically effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 27, 2019
    Assignee: AskAt Inc.
    Inventor: Takako Okumura
  • Patent number: 10370378
    Abstract: The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: August 6, 2019
    Assignee: EVOTEC INTERNATIONAL GMBH
    Inventors: John Alan Kemp, Ian Michael Hunneyball, Timothy Tasker
  • Patent number: 10344034
    Abstract: Methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives are described. Specifically, methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 9, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Patent number: 10342802
    Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: July 9, 2019
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin
  • Patent number: 10327999
    Abstract: Aerosol compositions, comprising a) at least one propellant and b) at least one cosmetic preparation, including (i) at least one strengthening active substance and (ii) at least one alkoxylated carboxylic acid ester of the following formula (I), in which R1 represents a straight-chain or branched, saturated or unsaturated alkyl group having 6 to 24 carbon atoms, R2 represents hydrogen or an alkyl group having 1 to 4 carbon atoms, R3 and R4 represent, independently of each other, hydrogen or an alkyl group having 1 to 4 carbon atoms, R5 represents a straight-chain or branched, saturated or unsaturated alkyl group having 6 to 24 carbon atoms or a phenyl group, and n and m represent, independently of each other, the numbers 0 or 1 to 20, are suitable for the application of hair cosmetic agents in the form of spray mists, quickly collapsing foams.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 25, 2019
    Assignee: Henkel AG & Co. KGaA
    Inventors: Thorsten Knappe, Ulrike Heinsohn
  • Patent number: 10328055
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro [cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 25, 2019
    Assignee: GRUENENTHAL GMBH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 10323011
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: June 18, 2019
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Patent number: 10314780
    Abstract: The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 11, 2019
    Assignee: MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBH
    Inventors: Heinz Polzer, Pierre-Paul Elena, Jürgen Senge